Last reviewed · How we verify

Fu-Sheng Wang — Portfolio Competitive Intelligence Brief

Fu-Sheng Wang pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Placebo & Entecavir Placebo & Entecavir marketed Nucleoside reverse transcriptase inhibitor (NRTI) Hepatitis B virus reverse transcriptase / HBV polymerase Virology / Hepatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 shared drug class
  2. Asan Medical Center · 1 shared drug class
  3. Avexa · 1 shared drug class
  4. Bristol-Myers Squibb · 1 shared drug class
  5. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  6. Dong-A ST Co., Ltd. · 1 shared drug class
  7. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fu-Sheng Wang:

Cite this brief

Drug Landscape (2026). Fu-Sheng Wang — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fu-sheng-wang. Accessed 2026-05-15.

Related